VANCOUVER, Nov. 4, 2014 /PRNewswire/ - iCo
Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF),
today announced that presentations regarding the company's Oral
Amphotericin B drug candidate will be made at the American
Association of Pharmaceutical Scientists (AAPS) Annual Meeting and
Exposition. The event takes place at the San Diego Convention Center November 2 – 6.
Dr. Kishor M. Wasan, Professor
and Dean, College of Pharmacy and
Nutrition at the University of
Saskatchewan, will present the following:
- Poster on November 4 between 9:30
and 12:30: T2099 - Novel Oral Amphotericin B Formulation Remains
Highly Effective against Murine Systemic Candidiasis following
Exposure to Tropical Temperature
- Panel Moderation on November 5
from 9:00 – 11:00: Antimicrobials, Super BUGS and Global
Health
- Presentation on November 5 from
2:25 to 2:50: Development of a Tropically Stable Oral Lipid
Formulation of Amphotericin B for the Treatment of Systemic Fungal
Infections and Visceral Leishmaniasis
Dr. Kishor Wasan, along with Dr.
Ellen Wasan, Assistant Professor,
College of Pharmacy and Nutrition, University
of Saskatchewan, invented the delivery technology at the
University of British Columbia in
2008.
About iCo Therapeutics
iCo Therapeutics in-licenses
and redefines existing drug candidates or generics by employing
reformulation and delivery technologies for new or expanded use
indications. The Company has exclusive worldwide rights to iCo-007
and iCo-008, as well as an oral drug delivery platform. The first
platform candidate being tested is the Oral Amp B Delivery system,
utilizing a known anti-fungal drug to treat latent HIV reservoirs,
parasitic and life-threatening infectious diseases. iCo trades on
the TSX Venture Exchange under the symbol "ICO" and the OTCQX under
the symbol "ICOTF". For more information, visit the Company website
at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the
content of this press release. Neither the TSX Venture Exchange nor
its Regulatory Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
Forward Looking Statements
Certain statements
included in this press release may be considered forward-looking
statements" within the meaning of applicable securities laws.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will," and similar references to future periods
and includes, but is not limited to, statements about the intended
use of proceeds of the Offering. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
iCo's current beliefs as well as assumptions made by and
information currently available to iCo and relate to, among other
things, anticipated financial performance, business prospects,
strategies, regulatory developments, market acceptance and future
commitments. Readers are cautioned not to place undue reliance on
these forward-looking statements, which are based only on
information currently available to iCo and speak only as of the
date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo in its
public securities filings and on its website, actual events may
differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.